Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Page 1
The VertiGO! Trial protocol: A prospective, single-center, patient-blinded study to evaluate efficacy and safety of prolonged daily stimulation with a multichannel vestibulocochlear implant prototype in bilateral vestibulopathy patients.
Vermorken BL, Volpe B, van Boxel SCJ, Stultiens JJA, van Hoof M, Marcellis R, Loos E, van Soest A, McCrum C, Meijer K, Guinand N, Pérez Fornos A, van Rompaey V, Devocht E, van de Berg R. Vermorken BL, et al. Among authors: meijer k. PLoS One. 2024 Mar 28;19(3):e0301032. doi: 10.1371/journal.pone.0301032. eCollection 2024. PLoS One. 2024. PMID: 38547135 Free PMC article.
DISCUSSION: The proposed schedule of fitting, stimulation and outcome testing allows for a comprehensive evaluation of the feasibility and long-term safety of a multichannel VCI prototype. This design will give insights into vestibular and hearing performance during VCI st …
DISCUSSION: The proposed schedule of fitting, stimulation and outcome testing allows for a comprehensive evaluation of the feasibility and l …
Tailored anticoagulant treatment after a first venous thromboembolism: protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study - cohort-based randomised controlled trial.
Burggraaf-van Delft JLI, van Rein N, Bemelmans RHH, van den Berg JK, Bruggeman CY, Cloos-van Balen M, Coppens M, Eefting M, Ende-Verhaar Y, van Es N, van Guldener C, de Jong WK, Kleijwegt F, Koster T, Kroon C, Kuipers S, Leentjens J, Luijten D, Mairuhu ATA, Meijer K, van de Ree MA, Roos R, Schrover I, Swart-Heikens J, van der Velden AWG, van den Akker-van Marle EM, le Cessie S, Geersing GJ, Middeldorp S, Huisman MV, Klok FA, Cannegieter SC; L-TRRiP investigators. Burggraaf-van Delft JLI, et al. Among authors: meijer k. BMJ Open. 2024 Mar 23;14(3):e078676. doi: 10.1136/bmjopen-2023-078676. BMJ Open. 2024. PMID: 38521524 Free PMC article.
The aim of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study is to evaluate the outcomes of tailored duration of long-term anticoagulant treatment based on individualised assessment of rVTE and major bleeding risks. ...
The aim of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study is to evaluate the outcomes of tailored duration of long-term …
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
Coppens M, Pipe SW, Miesbach W, Astermark J, Recht M, van der Valk P, Ewenstein B, Pinachyan K, Galante N, Le Quellec S, Monahan PE, Leebeek FWG; HOPE-B Investigators. Coppens M, et al. Lancet Haematol. 2024 Apr;11(4):e265-e275. doi: 10.1016/S2352-3026(24)00006-1. Epub 2024 Mar 1. Lancet Haematol. 2024. PMID: 38437857 Clinical Trial.
We report post-hoc 24-month efficacy and safety data from this trial to evaluate the longer-term effects of etranacogene dezaparvovec in individuals with haemophilia B. ...
We report post-hoc 24-month efficacy and safety data from this trial to evaluate the longer-term effects of etranacogene dezaparvovec …
Gait and dynamic pedobarographic analyses in hallux rigidus patients treated with Keller's arthroplasty, arthrodesis or cheilectomy 22 years after surgery.
de Bot R, Stevens J, Smeets T, Witlox A, Beertema W, Hendrickx R, Meijer K, Schotanus M. de Bot R, et al. Among authors: meijer k. PeerJ. 2023 Nov 20;11:e16296. doi: 10.7717/peerj.16296. eCollection 2023. PeerJ. 2023. PMID: 38025694 Free PMC article.
MOXFQ scores in all domains (walking/standing, range 21.4-24.1; pain, range 16.5-22.2 and social interaction, range 23.8-35.4) were not clinically and statistically different (P > 0.05) between the three different surgical interventions. CONCLUSION: These results suggest no lo …
MOXFQ scores in all domains (walking/standing, range 21.4-24.1; pain, range 16.5-22.2 and social interaction, range 23.8-35.4) were not clin …
Chronic thromboembolic pulmonary hypertension and clot resolution after COVID-19-associated pulmonary embolism.
de Jong CMM, Visser C, Bemelmans RHH, Boersma WG, van den Borst B, Burggraaf JLI, Cannegieter SC, Ten Cate-Hoek AJ, Croles FN, Faber HJ, Faber LM, Hellemons ME, Hessels LM, Huisman MV, Kamphuisen PW, Koster SCE, Kroft LJM, van der Lee I, Leentjens J, Meijer K, Ninaber MK, Sondermeijer BM, Stads S, Vonk Noordegraaf A, Winckers K, Kruip MJHA, Klok FA; Dutch COVID & Thrombosis Coalition investigators. de Jong CMM, et al. Among authors: meijer k. Eur Respir J. 2023 Apr 20;61(4):2300171. doi: 10.1183/13993003.00171-2023. Print 2023 Apr. Eur Respir J. 2023. PMID: 37080574 Free PMC article.
The results of this study suggest that CTEPH is not a more common long-term complication after COVID-19-associated PE than after PE in non-COVID-19 patients, and thrombus resolution did not seem to be different from non-COVID-19-associated PE https://bit.ly/3IjvWL3 The inc …
The results of this study suggest that CTEPH is not a more common long-term complication after COVID-19-associated PE than after PE i …
Long-Term Trends of Coagulation Parameters in People Living With HIV Treated With Combined Antiretroviral Therapy.
Bhoelan S, Borjas Howard J, Tichelaar V, Bierman W, Meijer K. Bhoelan S, et al. Among authors: meijer k. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231165492. doi: 10.1177/10760296231165492. Clin Appl Thromb Hemost. 2023. PMID: 36972487 Free PMC article.
Trends of coagulation parameters during long-term treatment with combination antiretroviral therapy (cART) are unclear. ...This study indicates that decreasing immune activation by cART reverses the procoagulant state in HIV partially during the first year. These parameter …
Trends of coagulation parameters during long-term treatment with combination antiretroviral therapy (cART) are unclear. ...This study …
Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin.
Bistervels IM, Bavalia R, Beyer-Westendorf J, Ten Cate-Hoek AJ, Schellong SM, Kovacs MJ, Falvo N, Meijer K, Stephan D, Boersma WG, Ten Wolde M, Couturaud F, Verhamme P, Brisot D, Kahn SR, Ghanima W, Montaclair K, Hugman A, Carroll P, Pernod G, Sanchez O, Ferrari E, Roy PM, Sevestre-Pietri MA, Birocchi S, Wik HS, Hutten BA, Coppens M, Naue C, Grosso MA, Shi M, Lin Y, Quéré I, Middeldorp S; Hokusai PTS Investigators. Bistervels IM, et al. Among authors: meijer k. Res Pract Thromb Haemost. 2022 Jul 1;6(5):e12748. doi: 10.1002/rth2.12748. eCollection 2022 Jul. Res Pract Thromb Haemost. 2022. PMID: 35992565 Free PMC article.
BACKGROUND: Postthrombotic syndrome (PTS) is a long-term complication after deep vein thrombosis (DVT) and can affect quality of life (QoL). ...OBJECTIVES: To compare the prevalence of PTS after acute DVT and the long-term QoL following DVT between patients treated …
BACKGROUND: Postthrombotic syndrome (PTS) is a long-term complication after deep vein thrombosis (DVT) and can affect quality of life …
SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders.
Cnossen MH, van Moort I, Reitsma SH, de Maat MPM, Schutgens REG, Urbanus RT, Lingsma HF, Mathot RAA, Gouw SC, Meijer K, Bredenoord AL, van der Graaf R, Fijnvandraat K, Meijer AB, van den Akker E, Bierings R, Eikenboom JCJ, van den Biggelaar M, de Haas M, Voorberg J, Leebeek FWG; SYMPHONY consortium. Cnossen MH, et al. Among authors: meijer k. J Thromb Haemost. 2022 Jun 2;20(9):2001-11. doi: 10.1111/jth.15778. Online ahead of print. J Thromb Haemost. 2022. PMID: 35652368 Free PMC article.
We believe that these research investments will lead to health care innovations with long-term clinical and societal impact. This consortium has been made possible by a governmental, competitive grant from the Netherlands Organization for Scientific Research (NWO) within t …
We believe that these research investments will lead to health care innovations with long-term clinical and societal impact. This con …
Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study).
Goedhart TMHJ, Bukkems LH, Coppens M, Fijnvandraat KJ, Schols SEM, Schutgens REG, Eikenboom J, Heubel-Moenen FCJI, Ypma PF, Nieuwenhuizen L, Meijer K, Leebeek FWG, Mathôt RAA, Cnossen MH. Goedhart TMHJ, et al. Among authors: meijer k. TH Open. 2022 Feb 3;6(1):e60-e69. doi: 10.1055/a-1760-0105. eCollection 2022 Jan. TH Open. 2022. PMID: 35280975 Free PMC article.
In resource-rich countries, almost all severe hemophilia patients receive prophylactic replacement therapy with factor concentrates to prevent spontaneous bleeding in joints and muscles to decrease the development of arthropathy and risk of long-term disability. Pharmacoki …
In resource-rich countries, almost all severe hemophilia patients receive prophylactic replacement therapy with factor concentrates to preve …
Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A.
Sanabria M, Álvarez Román MT, Castaman G, Janbain M, Matsushita T, Meijer K, Oldenburg J, Friedl S, Reding MT. Sanabria M, et al. Among authors: meijer k. BMJ Open. 2021 Sep 2;11(9):e044997. doi: 10.1136/bmjopen-2020-044997. BMJ Open. 2021. PMID: 34475142 Free PMC article.
Primary outcomes are total bleeding events and annualised bleeding rate; secondary outcomes include long-term safety, joint health, pharmacokinetics, patient-reported outcomes (PROs) from validated questionnaires and perioperative haemostasis. ...
Primary outcomes are total bleeding events and annualised bleeding rate; secondary outcomes include long-term safety, joint health, p …
35 results